Clinical Trial Update: Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the immunogenicity and safety of a meningococcal ACYW135 polysaccharide conjugate vaccine in children aged 3 to 35 months (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• Meningococcal ACYW135 polysaccharide conjugate vaccine (Meningococcal conjugate vaccine ACYW135)

Snippet

Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Conditions: Meningitis, Meningococcal | Phase 2 | Status: COMPLETED